 |
 |
Some comments on Dr. Fahn's welcome response to the alarming BMJ report about Eldepryl: - Table 3 of the report does give a sketchy unsatisfying comparison of "cause of death" between levodopa-only and levodopa plus Eldepryl. - The final paragraph of the report does mention that patients getting Eldepryl (as the study continues) will be advised to withdraw selegiline (Eldepryl) from their treatment regimens. - In view of the widespread use of Eldepryl and the long, sometimes acrimonious dispute over its efficacy, and the seriousness of the charge against its safety, I would respectfully suggest that an authoritative response such as Dr. Fahn's should be heard by an audience much larger than the 1000 or so members of this forum. - I personally have been taking Eldepryl for about a month, find it very beneficial, and had already decided to keep on taking it unless and until my neurologist declines to renew the prescription. For specific observations about the effects of Eldepryl, contact me privately. Cheers, Joe J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks CA 91403